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ABSTRACT 
 
A library of novel pyridylchalcones were synthesised and screened against Trypanosoma 
brucei rhodesiense. Eight were shown to have good activity with the most potent 8 having 
an IC50 value of 0.29 µM. Cytotoxicity testing with human KB cells showed a good 
selectivity profile for this compound with a selectivity index of 47. Little activity was seen 
when the library was tested against Leishmania donovani. In conclusion, pyridylchalcones 
are promising leads in the development of novel compounds for the treatment of human 
African trypanosomiasis (HAT). 
 
Keywords: Neglected tropical disease; Trypanosoma brucei rhodesiense; Leishmania 
donovani; pyridylchalcone; Claisen-Schmidt. 
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1. Introduction 
 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic 
disease transmitted by the bite of tsetse flies. It occurs in 36 countries in sub-Saharan 
Africa, where millions of people are at risk of infection [1-3]. HAT is caused by 2 sub-
species of Trypanosoma brucei and exists as a chronic infection with T. b. gambiense or as 
an acute infection with T. b. rhodesiense. Untreated, both forms are usually fatal [1-3]. 
There are two clinical stages in the progression of HAT. The first corresponds to the 
multiplication of the parasites in the blood and lymphatic system.  The second occurs when 
these cross the blood-brain barrier to infect the central nervous system causing 
neurological symptoms to appear. Stage 1 can be treated with pentamidine and suramin 
whereas melarsoprol, eflornithine, and their combinations with nifurtimox are the only 
treatments for stage 2. All of these drugs suffer from serious drawbacks including low 
efficacy, severe toxic side effects and the need for parenteral administration [1-3]. With no 
vaccine available and limited therapeutic alternatives the continuing emergence of drug 
resistance is seen as a major public health problem [4]. An urgent need exists for the 
development of more effective, less toxic and orally available treatments for this neglected 
tropical disease. 
  
Chalcones (1,3-diphenyl-2-propen-1-ones) are a major class of natural products often found 
in edible plants. They have received considerable attention due to their wide range of 
biological actions and have been used as a scaffold in the development of anticancer, 
antioxidant, antiangiogenic, and anti-inflammatory agents [5].  A number of natural and 
synthetic chalcones have been shown to possess anti-parasitic activities including 
licochalcone A 1, a natural prenylated chalcone isolated from liquorice root (Glycyrrhiza 
glabra), and a potent anti-leishmanial agent [6]. However, the therapeutic use of chalcones 
has been limited due to their poor bioavailability and rapid metabolic clearance from 
biological systems [7]. Nevertheless, hybrid molecules incorporating the chalcone moiety 
are emerging as promising leads for targeting Leishmania and Trypanosoma species [8-
11]. For example, the chalcone-benzoxaborole hybrid 2 gave 100% mouse survival rate 
and complete elimination of parasites in a T. b. brucei murine model [9].  
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Pyridylchalcones, such as 3 and 4, have been found to exhibit both antimalarial and anti-
leishmanial activity [6, 11, 12, 13]. However, there are no examples of them being tested 
against Trypanosoma brucei. With the antitrypanosomal activity of chalcone hybrids in mind 
[8-11], we were intrigued to determine whether pyridylchalcones would also be active 
against this target. It was anticipated that pyridyl analogues would exhibit the same low 
toxicity shown by compounds containing the chalcone nucleus but with improved 
bioavailability [14]. The introduction of a pyridine group will reduce the lipophilicity of the 
molecule and increase water solubility, both of which should ease formulation. In addition, 
lowering the lipophilicty of a chalcone and the inclusion of a heterocyclic A-ring has been 
associated with an increase in anti-parasitic activity [15].  
 
We report here the synthesis and in vitro evaluation of a series of novel pyridylchalcones 
against T. b. rhodesiense and L. donovani. Their cytotoxicity against human KB cells was 
also determined to establish their selectivity profile. 
 
2. Chemistry  
 
Attempts to prepare the 3-(3-pyridyl)chalcone 8 using standard Claisen-Schmidt conditions 
with 2 equivalents of aqueous sodium hydroxide in methanol yielded an unexpected result 
[16]. Instead of the desired chalcone, recrystallization from ethanol afforded the diketone 7 
in 25% yield (Scheme 1). This product presumably results from conjugate addition of the 
enolate of 3-bromoacetophenone to the previously formed chalcone. Similar results were 
obtained when using 3-chloroacetophenone and 4-chloroacetophenone. To our knowledge 
this unusual reactivity has not previously been reported for 3-pyridinecarboxaldehyde 5, 
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Fig. 1. Anti-parasitic chalcones 
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although it has been observed with both 2-pyridinecarboxaldehyde and 2-
quinolinecarboxaldehyde when reacted with acetophenone under similar conditions [17]. 
The addition of one equivalent of pyridine to these reactions was found to prevent this 
conjugate addition. This was thought to be due to the pyridine competing with the aldolate 
nitrogen for chelation of the metal ion in the intermediate. Unfortunately, this result was not 
repeated when one equivalent of pyridine was added to our reaction. 
 
Bhagat et al report good yields of chalcone with all three isomers of pyridinecarboxaldehyde 
when reacted with 4-methoxyacetophenone and 10% lithium hydroxide monohydrate in 
ethanol [18]. Using these conditions, we obtained 8 in a disappointing yield of 39%. It was 
clear from TLC that 7 was still being formed during this reaction. This proved difficult to 
remove by recrystallization from ethanol, and column chromatography was required to 
obtain pure 8. In a bid to improve yields and simplify purification we investigated the use of 
potassium hydroxide as a catalyst in 1,4-dioxane. This couple has been found to give good 
yields of quinoline-2-one based chalcones which had proved difficult to prepare using other 
conditions [19]. However, with 1.6 equivalents of potassium hydroxide we again obtained a 
mixture of 8 and 7. Maintaining 1, 4-dioxane as the solvent but changing the base to lithium 
hydroxide monohydarate proved the solution to our problems with 8 being obtained in 80% 
yield after recrystallization from ethanol. TLC showed little or no diketone formation. This 
method proved suitable for the synthesis of a range of pyridylchalcones (Table 1) in high 
yield. 
 
3. Results and discussion 
N
O O
N
Br Br
CHO Br
O
+
N
O
Br
(i)
(ii)5 6
8
7
Scheme 1. Reagents and conditions: (i) NaOH(aq), MeOH, 0°C then RT (25%). (ii) 
LiOH.H2O, 1,4-dioxane, RT (80%). 
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The activity of our chalcones against T. b. rhodesiense (STIB900) was determined using 
the Alamar blue growth inhibition assay [20]. Their cytotoxicity against human KB cells was 
also obtained in vitro (Table 1) allowing the calculation of a selectivity index (SI) for each 
compound where: SI = IC50 (KB cells)/ IC50 (T. b. r). Of the 17 compounds synthesised, 8 
showed good activity against T. b. rhodesiense (IC50 <0.2 mg/ mL), 8 moderate activity 
(IC50 0.2-3 mg/ mL) and 1 was inactive (IC50 > 3 mg/ mL). The most active compound, with 
an IC50 value of 0.29 µM, was 8 which contained a 3-pyridyl A-ring and a 3-bromophenyl B-  
Table 1. Antitrypanosomal activity and cytotoxicity of synthesized chalcones 
N° Ar (A-ring) Ar' (B-ring) IC50 / µM SIb 
T. b. 
rhodesiense 
STIB900a 
Cytotoxicity  
KB Cells 
7 
− − 
12.2 181 15 
8 3-Py- 3-Br-Ph- 0.29 13.5 47 
9 Ph- 3-Br-Ph- 0.96  18.4 19 
10 3-Py- Ph- 0.72  7.7 11 
11 3-Py- 3-MeO-Ph- 0.41 2.3 6 
12 3-Py- 4-Br-Ph- 0.34 7.9 23 
13 3-Py- 2-Br-Ph- 37.8 >300 >8 
14 3-Py- 2-MeO-Ph- 1.14 22.7 20 
15 3-Py- 4-MeO-Ph- 0.94 21.7 23 
16 3-Py- 3,4-(MeO)2-Ph- 0.98 22.8 24 
17 4-Py- 3-Br-Ph- 0.65 23.7 36 
18 2-Py- 3-Br-Ph- 0.40 14.7 37 
19 3-Br-Ph- 3-Py- 0.69 43.7 63 
20 3-Py- 3-Cl-Ph- 0.62 12.7 21 
21 3-Py- 3,4-(OCH2O)-Ph- 4.83 59.4 12 
22 3-Py- 3,4-F2-Ph- 0.72 20.7 29 
23 3-Py- 3-HO-Ph- 1.15 21.7 19 
24 3-Py- 3-Py- 1.02 17.0 17 
 Pentamidine  0.011 − − 
 Melarsoprol  0.005 − − 
 Podophyllotoxin  − 0.058 − 
a
 Values are the mean of two independent experiments in triplicate. 
b
 Selectivity index (SI) = IC50 KB cells/ IC50 T. b. rhodesiense STIB900. 
 
Ar Ar'OArCHO
+
CH3COAr' (i)
O O
N
Br Br
7
Scheme 2. Reagents and conditions: (i) LiOH.H2O, 1,4-dioxane, RT.  
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ring. This compound also showed good selectivity with an SI of 47. Although it was difficult 
to establish a clear structure activity relationship, certain trends were apparent. The 
presence of a pyridyl A-ring appears to be important for high activity. When this was 
replaced by a phenyl, as in 9, the activity dropped to 0.96 µM. The position of the nitrogen 
in the pyridine ring does not seem to be as crucial with the 2-pyridyl derivative 18 still 
having reasonable activity (IC50 = 0.40 µM). The 4-pyridyl derivative 17 had a lower IC50 
value of 0.65 µM but was still considered active. Modifying the B-ring while keeping a 3-
pyridyl A-ring can have a significant effect on activity. This was particularly apparent in 13 
and 14 which both have substituents at the 2-position in the B-ring. The latter with a 
methoxy group shows only moderate activity with an IC50 value of 1.14 µM, while the former 
with a bromo is our only inactive compound. Moving the bromo group in 8 to the para 
position produced a slight reduction in activity with 12 having an IC50 of 0.34 µM.  A more 
significant change was evident in 20 where the bromo group in 8 was replaced by a chloro 
resulting in a doubling of the IC50 value to 0.62 µM. With a methoxy group at the meta 
position in ring B, 11 showed reasonable activity (IC50 0.41 µM) but had a relatively low SI 
of 6. Moving the methoxy group to the para position significantly reduced activity with 15 
having an IC50 of 0.94 µM. The only other derivatives with an electron releasing group at 
this position, 16 (3,4-dimethoxy) and 21 (3,4-methylenedioxy), both exhibited only moderate 
activity suggesting that electron releasing groups in the B-ring are not conducive to high 
activity. The phenyl derivative 10 and its 3, 4-difluoro analogue 22 were both active with the 
same IC50 value of 0.72 µM.  The phenolic chalcone 23 had moderate activity with an IC50 
value of 1.15 µM. Taken in conjunction with our other results this could suggest that high 
activity is favoured by a hydrophobic group at the 3-position in the B-ring. A 3-pyridyl group 
in the B-ring is not optimum for activity with 19 and 24 giving only moderate IC50 values of 
0.69 and 1.02 µM respectively. The diketone 7 was found to be inactive. 
 
In view of the literature precedent [11, 12] and our above results with T. b. rhodesiense we 
decided to screen our compound library against Leishmania donovani [21]. Using HU3 
intracellular amastigotes at 30 µM only 8, 9, 12 and 20 showed any activity, with 39.7, 13.8, 
11.6 and 2.7% inhibition respectively. At 10 µM no inhibition was observed. Thus, although 
a number of our derivatives showed promise as potential antitrypanosomal agents they 
appear to have little activity against Leishmania. 
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4. Conclusion 
 
Initial attempts to prepare 3-pyridylchalcones using standard Claisen-Schmidt conditions 
with sodium hydroxide were unsuccessful resulting in the formation of a diketone. This 
problem was overcome by the use of lithium hydroxide monohydrate as base in 1, 4-
dioxane. Of the 17 derivatives synthesised eight were shown to have good activity against 
T. b. rhodesiense with the most active 8 having an IC50 value of 0.29 µM. This compound 
showed good selectivity with an SI of 47. Little activity was observed when the library was 
evaluated against L. donovani. In conclusion, pyridylchalcones are promising leads in the 
development of novel compounds for the treatment of HAT. 
 
5. Experimental section 
 
5.1 Synthetic chemistry 
 
5.1.1 General 
 All solvents and chemicals were used as purchased without further purification. The 1H and 
13C-NMR spectra were recorded on a Bruker Avance AV400 NMR spectrometer at 30°C. 
Chemical shifts are reported in δ units (ppm) relative to either TMS or the residual solvent 
signal. IR spectra were recorded as KBr discs on a Perkin-Elmer 298 spectrophotometer. 
HRMS was performed using a Thermo Scientific LTQ Orbitrap XL at the EPSRC UK 
National Mass Spectrometry Facility at Swansea University. Melting points (uncorrected) 
were determined on a Gallenkamp melting point apparatus in open glass capillary tubes. 
TLC was performed on Merck Silica Gel 60F254 coated plates. Plates were visualised under 
UV light (254/366nm) and stained with either 2, 4-dinitrophenylhydrazine, iodine or 
phosphomolybdic acid. Fluka silica gel 60 (30-45µ) was used for flash chromatography. 
Elemental analyses (C, H, N) was carried out by Warwick Analytical Services using a 
CE440 elemental analyser. Results were within ±0.4% of the theoretical values.  
 
5.1.2 1, 5-Di(3-bromophenyl)-3-(3-pyridyl)pentane-1,5-dione (7) 
Sodium hydroxide solution (0.8 mL, 50% w/v, 10.00 mmol) was added to a stirred and 
cooled (ice bath) solution of 3-bromoacetophenone (0.40 mL, 5.00 mmol) in ethanol (2.5 
mL). 3-Pyridinecarboxylate (0.47 mL, 5.00 mmol) was added and stirring continued for 2 h 
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before allowing the reaction to warm to RT. On the formation of a cream precipitate the 
reaction was quenched with water (30 mL) and the solid removed by filtration. After 
washing with water the solid was recrystallized from ethanol affording white crystals (0.305 
g, 25%). mp 152-154oC; 1H NMR (CDCl3): δ 3.32 (2H, dd, J = 6.6, 16.7 Hz), 3.54 (2H, dd, J 
= 6.6, 16.7 Hz), 4.08 (1H, quin, J = 6.6 Hz), 7.15-7.26 (2H, m), 7.36 (2H, t, J = 8.3, Hz), 
7.60-7.70 (2H, m), 7.86 (2H, d, J = 8.3 Hz), 8.07 (2H, s), 8.48 (1H, d, J = 1.2 Hz), 8.59 (1H, 
s); 13C NMR (CDCl3) δ 34.2, 44.2, 123.1, 123.5, 126.6, 130.3, 131.2, 135.4 136.3, 138.3, 
138.9, 148.4, 149.2, 196.4; IR (KBr) /cm-1 1678 (C=O); HRMS found [M+1]+ 485.9686, 
C22H17Br2NO2 requires [M+1]+ 485.9699; Anal. Calcd C22H17Br2NO2: C, 54.24; H, 3.52, N, 
2.88; Found C, 54.08; H, 3.54; N, 2.91. 
 
5.1.3 General method for chalcone synthesis 
Lithium hydroxide monohydrate (0.63 g, 14.95 mmol) was added to a stirred solution of the 
appropriate aldehyde (9.35 mmol) and ketone (9.35 mmol) in 1,4-dioxane (2.5 mL) at RT. 
Upon completion, as indicated by the formation of a precipitate and confirmed by TLC the 
reaction was quenched with water (30 mL). The resulting mixture was extracted with ethyl 
acetate (3x30 mL). The combined organic extracts were washed with brine (50 mL), dried 
(MgSO4) and the solvent removed under vacuum. The crude product was purified by either 
recrystallization from ethanol or flash chromatography on silica gel. 
 
 5.1.4 (E)-1-(3-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one (8)  
Recrystallization from ethanol. Pale yellow crystals (80%). mp 126-128oC; 1H NMR (DMSO-
d6): δ 7.51 (1H, dd, J = 7.4, 3.9 Hz), 7.56 (1H, t, J = 7.7 Hz), 7.81 (1H, d, J = 15.8 Hz), 7.87-
7.92 (1H, m), 8.11 (1H, d, J = 15.8 Hz), 8.16-8.19 (1H, m), 8.35-8.42 (2H, m), 8.64 (1H, dd, 
J = 2.1, 7.4 Hz), 9.06 (1H, d, J = 2.8 Hz); 13C NMR (DMSO-d6) δ 122.4, 123.4, 123.9, 127.6, 
130.37, 131.04, 135.31, 135.96,  139.27, 141.4, 150.5, 151.2, 187.7; IR (KBr) /cm-1 1665 
(C=O); HRMS found [M]+ 288.0025, C14H10BrNO requires [M]+ 288.0019; Anal. Calcd 
C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found C, 58.26; H, 3.44; N, 4.83. 
 
5.1.5  (E)-1-(3-Bromophenyl)-3-(phenyl)prop-2-en-1-one (9)  
Recrystallization from ethanol. Pale yellow crystals  (67%). mp 82-84oC; 1H NMR (DMSO-
d6): δ 7.44-7.47 (3H, m), 7.53 (1H, t, J = 9.2 Hz), 7.76 (1H, d, J = 15.3 Hz), 7.84-7.90 (3H, 
m), 7.93 (1H, d, J = 15.3 Hz), 8.14 (1H, dd, J = 1.2, 7.5 Hz), 8.30-8.34 (1H, m); 13C NMR 
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(DMSO-d6) δ 121.6, 122.1, 127.6, 128.1, 128.9, 130.5, 130.9, 139.5, 187.8; IR (KBr) /cm-1 
1661 (C=O); HRMS found [M+1]+ 288.0048, C15H11BrO requires [M+1]+ 288.0046; Anal. 
Calcd C15H11BrO: C, 62.74; H, 3.86; Found C, 62.38; H, 3.87. 
 
5.1.6 (E)-1-(Phenyl)-3-(3-pyridinyl)prop-2-en-1-one (10)  
Flash chromatography, 40% ethyl acetate: hexane. Lemon yellow solid (67%). mp 93-95oC; 
1H NMR (CDCl3): δ 7.36 (1H, dd, J = 4.9, 9.9 Hz), 7.49-7.56 (2H, m), 7.58-7.64 (2H, m), 
7.79 (1H, d, J = 14.8 Hz), 7.91-7.97 (1H, m), 8.00-8.07 (2H, m), 8.63 (1H, dd, J = 1.0, 4.9 
Hz), 8.62 (1H, d, J = 1.0 Hz); 13C NMR (CDCl3) δ 123.8, 128.6, 130.7, 132.9, 133.2, 134.6, 
137.7, 140.9, 150.0, 151.1, 189.8; IR (KBr) /cm-1 1660 (C=O); HRMS found [M+1]+ 
210.0913, C14H11NO requires [M+1]+ 210.0913; Anal. Calcd C14H11NO: C, 80.36; H, 5.30, 
N, 6.69; Found C, 80.36; H, 5.26; N, 6.60. 
  
5.1.7 (E)-1-(3-Methoxyphenyl)-3-(3-pyridinyl) prop-2-en-1-one (11)  
Flash chromatography, 50% ethyl acetate: hexane. Light yellow solid (70%). mp 83-84°C; 
1H NMR (CDCl3): δ 3.90 (3H, s), 7.15 (1H, dd, J = 3.7, 8.8 Hz), 7.36 (1H, dd, J = 4.7, 8.8 
Hz), 7.43 (1H, t, J = 8.4 Hz), 7.54-7.63 (3H, m), 7.79 (1H, d, J = 15.8 Hz), 7.93-7.98 (1H, 
m), 8.64 (1H, dd, J = 1.9, 4.7 Hz), 8.87 (1H, d, J = 2.7 Hz). 13C NMR (CDCl3): δ 55.5, 112.9, 
119.6, 120.8, 121.3, 123.8, 129.7, 130.7, 139.1, 140.9, 150.3, 151.1, 160.0, 189.5; IR (KBr) 
/cm-1 1663 (C=O); HRMS found [M+1]+ 240.1019, C15H13NO2 requires [M+1]+ 240.1019; 
Anal. Calcd C15H13NO2: C, 75.30; H, 5.48, N, 5.85; Found C, 75.53; H, 5.42; N, 5.67. 
 
5.1.8 (E)-1-(4-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one (12)   
Recrystallization from ethanol. Fine off white crystals  (80%). mp 126-128oC; 1H NMR 
(CDCl3): δ 7.36 (1H, dd, J = 5.3, 9.5 Hz), 7.54 (1H, d, J = 15.9 Hz), 7.65 (2H, d, J = 8.4 Hz), 
7.80 (1H, d, J = 15.8 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.93-7.98 (1H, m), 8.65 (1H, d, J = 3.1 
Hz), 8.86 (1H, s); 13C NMR (CDCl3): δ 123.2, 123.8, 128.3, 130.1, 130.5, 131.8, 134.6, 
141.5, 150.1, 151.3, 188.7; IR (KBr) /cm-1 1663 (C=O); HRMS found [M+1]+ 289.9997, 
C14H10BrNO requires [M+1]+ 289.9998; Anal. Calcd C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; 
Found C, 58.34; H, 3.46; N, 4.81. 
 
5.1.9 (E)-1-(2-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one (13)   
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Recrystallization from ethanol. Pale yellow crystals  (37%). mp 248-250oC (decomposed); 
1H NMR (CDCl3): δ 7.38-7.42 (2H, m), 7.52 (1H, d, J = 15.6 Hz), 7.67 (1H, dd, J = 2.2, 5.4 
Hz), 7.79 (1H, d, J = 15.6 Hz), 7.93-8.14 (2H, m), 8.15 (1H, t, J = 7.2 Hz), 8.65 (1H, d, J = 
4.7 Hz), 8.87 (1H, s); 13C NMR (CDCl3): δ 123.1,  127.0, 130.3, 131.6, 134.6, 136.0, 139.5, 
141.8, 150.2, 151.4, 186.1; IR (KBr) /cm-1 1666 (C=O); HRMS found [M+1]+ 289.9999, 
C14H10BrNO requires [M+1]+ 289.9998; Anal. Calcd C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; 
Found C, 58.30; H, 3.42; N, 4.88. 
 
5.1.10 (E)-1-(2-Methoxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one (14)   
Recrystallization from ethanol. Pale yellow crystals  (44%). mp 91-93oC; 1H NMR (DMSO-
d6): δ 3.91 (3H, s), 7.02 (1H, d, J = 8.3 Hz), 7.07 (1H, t, J = 7.5 Hz), 7.35 (1H, dd, J = 4.2, 
7.9 Hz), 7.48-7.54 (1H, m), 7.50 (1H, d, J = 15.8 Hz), 7.64 (1H, d, J = 15.8 Hz), 7.67 (1H, 
dd, J = 1.7, 7.5 Hz), 7.89 (1H, d, J = 7.9 Hz), 8.61 (1H, d, J = 4.2 Hz), 8.82 (1H, s); 13C 
NMR (CDCl3): δ 55.5, 11.4, 120.7, 123.5, 128.7 130.4, 130.6, 133.5, 134.7, 138.9, 149.9, 
150.8, 158.3, 192.1; IR (KBr) /cm-1 1656 (C=O); HRMS Found [M+1]+ 240.1017, C15H13NO2 
requires [M+1]+ 240.1019; Anal. Calcd C15H13NO2: C, 75.30; H, 5.48, N, 5.85; Found C, 
75.14; H, 5.58; N, 5.64. 
   
5.1.11 (E)-1-(4-Methoxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one (15) [12]  
Recrystallization from ethanol. Yellow solid (60%). mp 105-106°C; 1H NMR (CDCl3): δ 3.90 
(3H, s), 7.00 (2H, d, J = 8.8 Hz), 7.35 (1H, dd, J = 4.6, 8.3 Hz), 7.61 (1H, d, J = 16.2 Hz), 
7.78 (1H, d, J = 16.2 Hz), 7.92-7.96 (1H, m), 8.04 (2H, d, J = 8.8 Hz), 8.62 (1H, dd, J = 4.2, 
1.3 Hz), 8.87 (1H, d, J = 2.5 Hz); 13C NMR (CDCl3): δ 55.6, 114.0, 123.8, 130.7, 130.9, 
134.6, 137.4, 140.1, 149.9, 150.9, 163.7, 188.0; IR (KBr) /cm-1 1662 (C=O); HRMS found 
[M+1]+ 240.1017, C15H13NO2 requires [M+1]+ 240.1019; Anal. Calcd C15H13NO2.0.15H2O: 
C, 74.46; H, 5.54, N, 5.79; Found C, 74.41; H, 5.43; N, 5.77. 
 
5.1.12 (E)-1-(3, 4-Dimethoxyphenyl)-3-(3-pyridyl)prop-2-en-l-one (16)  
Flash chromatography, 60-80% ethyl acetate: hexane. Light yellow solid (67%). mp 91-
93°C; 1H NMR (CDCl3): δ 3.99 (6H, s), 6.94 (1H, d, J = 7.5 Hz), 7.36 (1H, dd, J = 5.0, 8.0 
Hz), 7.63 (1H, d, J = 15.9 Hz), 7.64 (1H, d, J = 2.0 Hz), 7.68 (1H, dd, J = 2.0, 7.5 Hz), 7.78 
(1H, d, J = 15.9 Hz), 7.93-7.96 (1H, m), 8.63 (1H, dd, J = 1.5, 5.0 Hz), 8.87 (1H, d, J = 1.5 
Hz); 13C NMR (CDCl3) δ 56.2, 110.0, 110.8, 122.7, 123.7, 124.5, 130.9, 134.6, 140.1, 
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149.40 149.9, 150.9, 153.7, 187.9; IR (KBr) /cm-1 1655 (C=O); HRMS found [M+1]+ 
270.1125, C16H15NO3 requires [M+1]+ 270.1125; Anal. Calcd C16H15NO3: C, 71.36; H, 5.61, 
N, 5.20; Found C, 71.03; H, 5.65; N, 5.14. 
 
5.1.13 (E)-1-(3-Bromophenyl)-3-(4-pyridinyl)prop-2-en-1-one (17)   
Recrystallization from ethanol. Pale yellow crystals  (34%). mp 104-106oC; 1H NMR 
(CDCl3): δ 7.34 (1H, t, J = 7.1 Hz), 7.41 (2H, d, J = 6.1 Hz), 7.53 (1H, d, J = 15.6 Hz), 7.64 
(1H, d, J = 15.6 Hz), 7.66-7.69 (1H, m), 7.87 (1H, dt, J = 1.0, 7.1 Hz), 8.07 (1H, t, J = 1.0 
Hz), 8.63 (2H, d, J = 6.1 Hz); 13C NMR (CDCl3): δ 122.1, 123.2, 125.4, 127.1, 130.4, 131.6, 
136.2, 139.2, 141.8, 142.4, 150.7, 188.4; IR (KBr) /cm-1 1666 (C=O); HRMS found [M+1]+ 
289.9998, C14H10BrNO requires [M+1]+ 289.9998; Anal. Calcd C14H10BrNO: C, 58.36; H, 
3.50, N, 4.86; Found C, 58.20; H, 3.46; N, 4.81. 
 
5.1.14 (E)-1-(3-Bromophenyl)-3-(2-pyridinyl)prop-2-en-1-one (18)   
Recrystallization from ethanol. Pale yellow crystals  (47%). mp 110-112oC; 1H NMR 
(CDCl3): δ 7.40-7.49 (2H, m), 7.55 (1H, t, J = 8.8 Hz), 7.72 (1H, d, J = 16.0 Hz), 7.85-8.00 
(2H, m), 8.10-8.15 (2H, m), 8.20 (1H, s), 8.70 (1H, d, J = 4.5 Hz); 13C NMR (CDCl3): δ 
125.0,  126.9, 127.5, 130.9, 135.7, 137.2, 143.8, 150.1, 152.6, 188.3; IR (KBr) /cm-1 1664 
(C=O); HRMS found [M+1]+ 289.0056, C14H10BrNO requires [M+1]+ 289.0052; Anal. Calcd 
C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found C, 58.30; H, 3.45; N, 4.86. 
  
5.1.15 (E)-3-(3-Bromophenyl)-1-(3-pyridinyl)prop-2-en-1-one (19)   
Recrystallization from ethanol. Pale yellow crystals  (40%). mp 114-116oC; 1H NMR 
(CDCl3): δ 7.32-7.44 (2H, m), 7.52 (1H, d, J = 16.5 Hz), 7.72 (1H, d, J = 6.5 Hz), 7.81 (1H, 
d, J = 16.5 Hz), 7.93-7.98 (2H, m), 8.14 (1H, t, J = 1.5Hz), 8.64 (1H, d, J = 2.7 Hz), 8.87 
(1H, s); 13C NMR (CDCl3): δ 123.1,  123.2, 126.6, 130.4, 131.6, 134.6, 136.0, 142.3, 150.2, 
151.4, 188.4; IR (KBr) /cm-1 1658 (C=O); HRMS found [M+1]+ 289.0055, C14H10BrNO 
requires [M+1]+ 289.0052; Anal. Calcd C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found C, 
58.30; H, 3.45; N, 4.81. 
 
5.1.16 (E)-1-(3-Chlorophenyl)-3-(3-pyridinyl)prop-2-en-1-one (20)  
Recrystallization from ethanol. Off white crystals  (65%). mp 128-130oC; 1H NMR (CDCl3): δ 
7.37 (1H, dd, J = 5.2, 7.7 Hz), 7.45 (1H, t, J = 6.6 Hz), 7.51-7.60 (2H,  m), 7.80 (1H, d, J = 
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16.0 Hz), 7.89 (1H, d, J = 7.6 Hz), 7.94-8.02 (2H, m), 8.65 (1H, d, J = 5.2 Hz), 8.86 (1H, s); 
13C NMR (CDCl3): δ  123.1, 123.8, 126.6, 128.6, 130.1, 130.4, 133.0, 135.1, 139.3, 141.8, 
150.2, 151.4, 188.4; IR (KBr) /cm-1 1665 (C=O); HRMS found [M+1]+ 244.0524, C14H10NOCl 
requires [M+1]+ 244.0524; Anal. Calcd C14H10NOCl: C, 69.00; H, 4.14, N, 5.75; Found C, 
68.86; H, 4.12; N, 5.66. 
 
5.1.17 (E)-1-(3,4-Methylenedioxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one (21) 
Recrystallization from ethanol. Off white crystals  (55%). mp 138-140oC; 1H NMR (CDCl3): δ 
6.10 (2H, s), 6.92 (1H, d, J = 7.8 Hz), 7.37 (1H, dd, J = 4.3, 7.1 Hz) 7.54 (1H, d, J = 2.1 Hz), 
7.57 (1H, d, J = 14.9 Hz) 7.67 (1H, dd, J = 2.1, 7.8 Hz), 7.78 (1H, d, J = 14.9 Hz), 7.93-7.98 
(1H, m), 8.63 (1H, dd, J = 1.1, 4.3 Hz), 8.86 (1H, d, J = 1.2 Hz); 13C NMR (CDCl3) δ 102.0, 
108.0, 109.4, 123.5, 123.8, 124.9, 130.8, 132.5, 134.6, 140.4, 148.5, 149.9, 151.0, 152.0, 
187.6; IR (KBr) /cm-1 1666 (C=O); HRMS found [M+1]+ 254.0811, C15H11NO3 requires 
[M+1]+ 254.0812; Anal. Calcd C15H11NO3: C, 71.14; H, 4.38, N, 5.53; Found C, 70.91; H, 
4.36; N, 5.48. 
  
5.1.18 (E)-1-(3,4-Difluorophenyl)-3-(3-pyridinyl)prop-2-en-1-one (22)   
Recrystallization from ethanol. Pale green crystals  (47%). mp 120-121oC; 1H NMR (DMSO-
d6): δ 7.50-7.53 (1H, m), 7.63-7.70 (1H, m), 7.78 (1H, d, J = 15.0 Hz), 8.10 (2H, d, J = 15.0 
Hz), 8.24-8.29 (1H, m),  8.37-8.39 (1H, m), 8.64 (1H, dd, J = 1.5, 4.3 Hz), 9.05 (1H, d, J = 
1.2, 4.3 Hz); 13C NMR (DMSO-d6) δ 117.9, 118.1, 123.1, 126.5, 130.3, 134.7, 141.4, 150.5, 
150.9, 186.5; IR (KBr) /cm-1 1661 (C=O); HRMS found [M]+ 246.0724, C14H9NOF2 requires 
[M]+ 246.0725; Anal. Calcd C14H9F2NO: C, 68.57; H, 3.70, N, 5.71; Found C, 68.48; H, 
3.70; N, 5.66. 
 
5.1.19 (E)-1-(3-Hydroxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one (23)   
After quenching with water the mixture was acidified with 1 M HCl before extraction with 
ethyl acetate. Recrystallization from ethanol. Light yellow crystals  (55%). mp 182-184oC; 
1H NMR (DMSO-d6): δ 7.09 (1H, dd, J = 2.1, 8.5 Hz), 7.39 (1H, t, J = 7.7 Hz)), 7.48-7.51 
(2H, m), 7.65 (1H, d, J = 6.8 Hz), 7.75 (1H, d, J = 14.9 Hz), 8.01 (1H, d, J = 14.9 Hz), 8.33 
(1H, d, J = 7.7 Hz)), 8.62 (1H, s), 9.02 (1H, s), 9.85 (1H, brs, OH); 13C NMR (DMSO-d6) δ 
114.7, 119.7, 120.5, 123.9, 124.1, 129.9, 135.1, 138.7, 140.4, 150.3, 157.8, 188.9; IR (KBr) 
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/cm-1 1660 (C=O); HRMS found [M+1]+ 226.0861, C14H11NO2 requires [M+1]+ 226.0863;  
Anal. Calcd C14H11NO2: C, 74.65; H, 4.92, N, 6.22; Found C, 74.51; H, 4.92; N, 6.03. 
 
5.1.20 (E)-1-(3-pyridinyl)-3-(3-pyridinyl)prop-2-en-1-one (24)   
Recrystallization from ethanol. Pale yellow crystals  (41%). mp 148-150oC; 1H NMR 
(DMSO-d6): δ 7.51 (1H, dd, J = 4.8, 9.0 Hz), 7.62 (1H, dd, J = 4.8, 9.0 Hz), 7.83 (1H, d, J = 
13.7 Hz), 8.12 (1H, d, J = 13.7 Hz), 8.38 (1H, d, J = 7.2 Hz), 8.48 (1H, d, J = 7.2 Hz),  8.63 
(1H, d, J = 4.8 Hz), 8.85 (1H, d, J = 4.8 Hz), 9.06 (1H, s), 9.37 (1H, s); 13C NMR (DMSO-d6) 
δ 123.6, 123.9, 130.3, 132.5, 135.3, 141.3, 149.8, 151.3, 153.5, 188.3; IR (KBr) /cm-1 1666 
(C=O); HRMS found [M+1]+ 211.0864, C13H10N2O requires [M+1]+ 211.0866; Anal. Calcd 
C13H10N2O: C, 74.27; H, 4.79, N, 13.33; Found C, 73.90; H, 4.79; N, 13.36. 
 
5.2 Biological assays 
 
5.2.1 Trypanocidal activity 
Trypanosoma brucei rhodesiense STIB 900, a clone of a population isolated in 1982 from a 
patient in Tanzania. Stock drug solutions were prepared in DMSO at 20 mM and further 
diluted to the appropriate concentration using medium. Assays were performed in 96-well 
microtiter plates with each well containing 100 ml of parasite culture (1 x 103 bloodstream 
forms) with serial drug dilutions at 37°C for 72 h in 5% CO2. Each compound was tested in 
triplicate with 30 mg/ml the highest concentration of compound used and a 3-fold serial 
dilution was performed down to a suitable concentration to obtain an IC50 value. Control 
wells were without drug and blanks were medium only. After 72 h of incubation the plates 
were inspected to assure growth in control wells and to determine the minimum inhibitory 
concentration (MIC). Subsequently, 20 µL of Alamar Blue™ was added to each well and the 
plates incubated for another 2-4 h. Plates were read on a Gemini Plate Reader (Molecular 
Devices) using an excitation wave length of 530 nm and an emission wave length of 580 
nm (cut off 550 nm). IC50 values were calculated using Prism © software. Pentamidine and 
melarsoprol were used as positive controls. 
 
5.2.2 Toxicity on KB cells 
KB cells, derived from a human carcinoma of the nasopharynx and typically used in assays 
for antineoplastic agents, were maintained in RPMI 1640 medium (Sigma, UK), 10% heat-
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inactivated foetal calf serum, 37°C, 5% CO2. KB cell monolayers, prepared in 96-well 
plates, were exposed to the test compounds for 72 h. Podophyllotoxin was used as a 
positive control. 20 µL of Alamar Blue™ was added to each well. After a further 2–4 h 
incubation the plates were read (Molecular Devices Gemini™) at EX/EX 530/580, cut-off 
550 nm. The IC50 values were calculated by sigmoidal regression analysis (Prism ©). 
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Highlights 
• Improved Claisen-Schmidt condensation using lithium hydroxide monohydrate 
in 1,4-dioxane. 
• Pyridylchalcones show good activity and selectivity against Trypanosoma 
brucei. 
• Pyridylchalcones show little activity against Leishmania donovani. 
• Promising leads in the development of novel compounds for the treatment of 
sleeping sickness. 
